HCV infection, B-cell non-Hodgkin’s lymphoma and immunochemotherapy: Evidence and open questions

• DOI: 10.4251/wjgo.v4.i3.46
• Publication Date: 2012-03-15T14:14:18Z
• Authors: Maria Christina Cox
• Keywords: Hepatitis C

There is plenty of data confirming that hepatitis C virus (HCV) infection a predisposing factor for B-cell non-Hodgkin's lymphoma (B-NHL) outbreak, while relatively few reports have addressed the role HCV in affecting B-NHL patients' outcome. may influence short-term outcome because emergence severe hepatic toxicity (HT) during immunochemotherapy. Furthermore, long term HCV-related liver disease and quality life will possibly be affected by Rituximab maintenance, multiple-lines chemotherapy hematopoietic stem cell transplantation. In this review, dealing with aggressive low-grade were separately analyzed. The retrospective papers reporting on patients showed risk outbreak HT treatment. This adverse event not infrequently leads to reduction treatment density intensity. Existing report more widespread disease, frequent relapses or lower ORR compared HCV-negative patients. Notwithstanding that, there no statistical evidence prognosis HCV-positive inferior subjects. prospective studies longer follow-up are necessary ascertain if outcomes sequels immunochemotherapies progression disease.